Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $5.8 million.

  • Enanta Pharmaceuticals' Gains from Investment Securities fell 72.63% to $98,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $2.0 million, marking a year-over-year decrease of 92.26%. This contributed to the annual value of $5.8 million for FY2025, which is 11.09% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Gains from Investment Securities of $5.8 million as of FY2025, which was up 11.09% from $5.2 million recorded in FY2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Gains from Investment Securities peaked at $5.8 million during FY2025, and registered a low of $3.9 million during FY2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $5.2 million (2024), whereas its average is $5.1 million.
  • Data for Enanta Pharmaceuticals' Gains from Investment Securities shows a peak YoY increased of 18.76% (in 2024) over the last 5 years.
  • Over the past 5 years, Enanta Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $3.9 million in 2021, then increased by 3.66% to $4.0 million in 2022, then increased by 9.32% to $4.4 million in 2023, then climbed by 18.76% to $5.2 million in 2024, then climbed by 11.09% to $5.8 million in 2025.